DIADEM US INC
MISSION
To continue research, development and support commercialisation of AlzoSure® Predict in North America.
To continue to validate AlzoSure® Predict on multiple and numerous clinical cohorts of various demographics and ethnicities from North America.
COMPANY LEADERSHIP
MICHAEL RASCHE
President and Chief Executive Officer
Michael Rasche is currently Chief Executive Officer (CEO) and a member of the Board of Directors of Diadem SpA. Rasche has more than three decades of experience in driving life sciences industry innovation and growth, along with a uniquely broad cultural perspective gained from building and leading businesses based in nine countries across Europe and the Americas.
PAUL KINNON
Chairman of the board
Paul has over 30 years of experience in the global life sciences industry, with an executive career focused on Clinical Diagnostics and innovative products to improve patients’ lives. He has held leadership positions within various companies, raising more than $70m in funding and creating global partnerships. Paul’s experience living and working in the USA gives him a novel and unique outlook on the global industry.
SAM AGUS
Chief Medical Officer
Sam is board-certified neurologist and a seasoned medication and device (including software as medical device) development expert, with more than 20 years of global experience in multiple therapy areas. He has served as Chief Medical Officer with several biotech companies and senior leader in clinical development and medical affairs in various mid-size and large pharmaceutical companies, such as H. Lundbeck A/S, Shire Plc., Abbott Labs, Solvay Pharmaceuticals, and Teva Pharmaceutical industry.
Contact:
Tel no.: 1 858 215 6250
Address:
Diadem US, Inc.
1117 S. California Avenue
Palo Alto, CA94304
Discover the latest opportunities
For job postings, the latest updates and more on the AlzoSure Predict® , click the button below.